Biomarker Evaluation in Advanced Stage Cervical Cancer by an International Working Group. Tumor Stages (1B1 - 4)
Prospective Multicentric European trial for Cervical cancer, not previously treated, with tumour biopsies, and blood collection for molecular analysis at predetermined time points.
Cervical Cancer
PROCEDURE: Tumor biopsies|PROCEDURE: Blood sampling
Correlation between tumor biological profile and treatment response., Dominant mutations and activation pathways in cervical cancers is assessed from tumor biopsies., up to 6 months
Progression Free Survival evaluation, Number of patient with no local/metastasis relapse 18 months after end of primary treatment course., up to 18 months|Standard treatment description (Description of primary treatment course regarding : - Initial FIGO ( International Federation of Gynecology and Obstetrics ) staging at baseline - Geographic location(country), Description of primary treatment course regarding :

* Initial FIGO ( International Federation of Gynecology and Obstetrics

  ) staging at baseline
* Geographic location(country), up to six months|Standard treatment's side effects description (assessed by compiling grade 3 and 4 sides effects during and after treatment (according to NCI CTCAE v4.03 scale - National Cancer Institute Common Toxicity Criteria for Adverse Effects), Description of standard treatment's side effects will be assessed by compiling grade 3 and 4 sides effects during and after treatment (according to NCI CTCAE v4.03 scale, up to 6 months|Molecular tumor alterations description (Description of molecular tumor alterations regarding geographic location (country), Description of molecular tumor alterations regarding geographic location (country), up to 24 months
Prospective Multicentric European trial for Cervical cancer, not previously treated, with tumour biopsies, and blood collection for molecular analysis at predetermined time points.